Elevidys, which costs $3.2 million for a one-time infusion, was the first gene therapy approved in the U.S. for Duchenne ...

A patient has died while taking a closely watched gene therapy for muscular dystrophy. Sarepta Therapeutics announced the ...

With revenues climbing steadily since 2022, Sarepta is just beginning to reap the benefits of Elevidys’ commercialization. In its most recent quarter, SRPT’s cost of sales was $132.3 million, while ...

Cambridge-based Sarepta Therapeutics said Tuesday that a patient died while taking its closely watched gene therapy for muscular dystrophy, sending company shares plummeting in morning trading.

Elevidys, which costs $3.2 million for a one-time infusion, was the first gene therapy approved in the U.S. for Duchenne muscular dystrophy, a rare condition that causes muscle weakness ...

Elevidys uses a disabled virus to insert a replacement gene for producing dystrophin into patient cells. It costs $3.2 million for a one-time treatment. Sarepta has received FDA accelerated ...